Keyphrases
ADAMTS13
31%
ADAMTS13 Protein
18%
Allogeneic Hematopoietic Cell Transplant Recipients
10%
Androgens
12%
Antigen Sensitivity
50%
Aplastic Anemia
50%
Asia
12%
B-stage
8%
Bone Marrow Failure
12%
Cancer Therapeutics-related Cardiac Dysfunction
50%
Candour
50%
Chimeric Antigen Receptor T-cell Therapy
21%
Cytomegalovirus Prophylaxis
33%
Daratumumab
50%
Gemtuzumab Ozogamicin
50%
Good's Syndrome
18%
Hematopoietic Stem Cell Transplantation
12%
Hepatic Veno-occlusive Disease
50%
High-dose Cytarabine
7%
High-risk Acute Leukemia
50%
Hyper-CVAD
21%
Hyper-CVAD Regimen
14%
Idiopathic Pneumonia Syndrome
50%
Immunosuppressive Therapy
12%
Letermovir
50%
Lipid Profiling
50%
Maternal Survival
50%
Multiple Myeloma Patients
50%
Myeloma Therapy
8%
National Cohort Study
50%
National Health Insurance Research Database (NHIRD)
12%
Patient Size
10%
Plasma Triglyceride Concentration
8%
PLASMIC Score
50%
Pomalidomide
50%
Population Database
50%
Post-transplant Outcomes
50%
Pregnancy-associated Cancer
50%
RHOA G17V
50%
Risk Prediction Score
50%
Severe Aplastic Anemia
12%
Subcutaneous Panniculitis-like T-cell Lymphoma (SPTCL)
8%
Symptomatic Relapse
18%
T Cell Purification
50%
Taiwan
12%
Thymectomy
43%
Transplant Registry
50%
Transplantation Autologous
8%
Treatment Outcome
50%
Triglyceride Hydrolysis
8%
Immunology and Microbiology
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Allogeneic Stem Cell Transplantation
12%
Anti-Thymocyte Globulin
10%
Antigen Specificity
7%
Apolipoprotein
8%
Autoimmune Hemolytic Anemia
16%
Autologous Hematopoietic Stem Cell Transplantation
5%
Autologous Stem Cell Transplantation
50%
Blood Plasma
25%
Carcinoembryonic Antigen
7%
Cell Viability
7%
Chimeric Antigen Receptor
58%
Chimeric Antigen Receptor T-Cell
100%
Chimeric Antigen Receptor T-Cell Therapy
37%
Cholesterol Blood Level
25%
Conditioning
5%
Cytokine Release
7%
Cytotoxicity
7%
Density Gradient
8%
Embase
16%
Genetic Screening
8%
Hematopoietic Stem Cell Transplantation
100%
High-Density Lipoprotein
33%
Human Herpesvirus 8
50%
Human immunodeficiency virus
50%
Human Immunodeficiency Virus Infection
12%
Immunodeficiency
12%
Lenalidomide
50%
Lipid Blood Level
50%
Lipid Homeostasis
8%
Lipoprotein
16%
Low-Density Lipoprotein
25%
Lymphoproliferative Disorders
50%
Magnetic-Activated Cell Sorting
7%
Mortality Rate
10%
Myeloid
50%
Organ Transplantation
50%
Peptides
7%
Serine
50%
T Cell
7%
T Cell Activation
7%
Therapeutic Research
5%
Triacylglycerol Blood Level
16%
Tumor Cell
7%
Medicine and Dentistry
All Cause Mortality
5%
Androgen
10%
Aplastic Anemia
50%
Bone Marrow Failure
10%
Bone Marrow Transplantation
50%
Cancer Therapy
50%
Cancer Treatment
16%
Cardiopulmonary Exercise Test
5%
Chimeric Antigen Receptor
37%
Chimeric Antigen Receptor T-Cell Immunotherapy
37%
Clinician
6%
Comorbidity Assessment
8%
Congestive Heart Failure
5%
Daratumumab
50%
Differential Diagnosis
6%
Effusion
6%
First Year Postpartum
20%
Genetic Screening
8%
Hazard Ratio
5%
Heart Left Ventricle Failure
5%
Hematopoietic Cell
35%
Hematopoietic Stem Cell Transplantation
10%
High Risk Population
5%
Human Herpesvirus 8
50%
Human immunodeficiency virus
50%
Human Immunodeficiency Virus Infection
6%
Idiopathic Pneumonia Syndrome
50%
Immune Deficiency
6%
Immunosuppressive Treatment
10%
Inotuzumab Ozogamicin
50%
Intermediate Risk Population
6%
Left Ventricular Systolic Dysfunction
5%
Lenalidomide
50%
Letermovir
50%
Multivariate Analysis
5%
Non-Hodgkin Lymphoma
6%
Organ Toxicity
7%
Organ Transplantation
50%
Oxygen Consumption
5%
Patient with Transplantation
10%
Philadelphia 1 Chromosome
10%
Posttransplant Lymphoproliferative Disease
50%
Primary Effusion Lymphoma
50%
Rare Disease
5%
Receptor Sensitivity
12%
Risk Stratification
10%
Scoring System
15%
T Cell Exhaustion
12%
Thymocyte Antibody
5%
Von Willebrand Factor Cleaving Proteinase
50%
